Skip to main content

Table 2 Laboratory results in normal control (NC), beta-thalassemic patients receiving regular blood transfusion (Thal-RT) and post-hematopoietic stem cell transplantation beta-thalassemic patients (Thal-HSCT)

From: No differences in hemostatic and endothelial activations between haploidentical and matched-donor hematopoietic stem cell transplantation in thalassemia disease

Parameter NC
n = 20
Thal-RT
n = 28
Thal-HSCT
Classified by type of donor
Haploidentical
n = 14
Matched-donor
n = 9
VWF:Ag (%) 80.8 (67.5–108.1) 131.3* (100.3–151.5) 149.7* (127.9–162.1) 139.4* (113.2–169.9)
TNF-α (pg/ml) 0.1 (0.0–2.2) 4.4* (3.1–5.3) 3.2 (2.8–4.4) 4.7* (3.8–5.2)
TM (ng/ml) 2.7 (2.3–3.4) ND 3.8 (2.5–4.2) 4.0 (3.5–5.5)
F1.2 (pmol/l) 125.5 (109.8–150.9) 404.1 (195.7–1048.0) 227.6# (173.2–281.2) 213.8 (190.1–271.5)
TAT (μg/l) 2.6 (2.4–3.0) 4.7 (2.0–7.0) 3.0 (2.6–4.0) 4.7 (3.7–6.3)
D-dimer (ng/ml) 224.0 (118.0–346.5) 287.2 (181.6–453.2) 254.0 (207.0–429.0) 410.0 (335.0–555.0)
  1. Abbreviations: vWF:Ag von Willebrand factor antigen; TNF-α tumor necrosis factor alpha; TM thrombomodulin; F1.2 prothrombin fragment 1 + 2; TAT thrombin-antithrombin complex; ND no data
  2. Data expressed as median (interquartile range)
  3. *, significant compared with NC, p-value < 0.05
  4. #, significant compared with Thal-RT, p-value < 0.05
  5. tested by Bonferroni